0000950170-24-080924.txt : 20240702
0000950170-24-080924.hdr.sgml : 20240702
20240702185644
ACCESSION NUMBER: 0000950170-24-080924
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240628
FILED AS OF DATE: 20240702
DATE AS OF CHANGE: 20240702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yale Catriona
CENTRAL INDEX KEY: 0001779308
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 241097696
MAIL ADDRESS:
STREET 1: C/O AKERO THERAPEUTICS INC.
STREET 2: 170 HARBOR WAY 3RD FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
ownership.xml
4
X0508
4
2024-06-28
0001744659
Akero Therapeutics, Inc.
AKRO
0001779308
Yale Catriona
601 GATEWAY BOULEVARD
SUITE 350
SOUTH SAN FRANCISCO
CA
94080
false
true
false
false
Chief Development Officer
false
Common Stock
2024-06-28
5
A
false
1064
19.941
A
75931
D
Ms. Yale is voluntarily reporting the acquisition of these shares on June 28, 2024 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).
In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on June 28, 2024.
/s/ Jonathan Young, Attorney-in-Fact
2024-07-02